What is the best dose and drug for severe insomnia in a patient with a history of zopiclone (eszopiclone) use and subsequent withdrawal?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Severe Insomnia Following Zopiclone Withdrawal

For severe insomnia after zopiclone discontinuation, initiate zolpidem 10 mg at bedtime (5 mg if elderly) as it effectively treats both sleep onset and maintenance insomnia with lower dependence risk than restarting zopiclone. 1, 2

Understanding Zopiclone Withdrawal

Your current insomnia is likely multifactorial, representing both withdrawal symptoms and the underlying sleep disorder that zopiclone was masking:

  • Zopiclone withdrawal can produce rebound insomnia, anxiety, palpitations, sweating, irritability, and in severe cases hallucinations, typically emerging 1-2 days after discontinuation 3
  • Physical dependence develops with chronic zopiclone use, particularly at higher doses or prolonged duration (you've been off since the date mentioned) 3, 4
  • The acute withdrawal phase typically resolves within 2-3 weeks, though sleep disturbances may persist longer 3

First-Line Treatment Recommendation

Cognitive Behavioral Therapy for Insomnia (CBT-I) should be initiated immediately as the foundation of treatment, even when adding pharmacotherapy. 1, 2

CBT-I components include:

  • Stimulus control: Leave bed if not asleep within 20 minutes, return only when drowsy 1
  • Sleep restriction: Limit time in bed to actual sleep time, gradually increasing 1
  • Cognitive restructuring: Address beliefs like "I can't sleep without medication" 1

Pharmacological Management Algorithm

Primary Recommendation: Zolpidem

Start zolpidem 10 mg at bedtime (5 mg if age ≥65 years or hepatic impairment). 1, 2, 5

Rationale for choosing zolpidem over other options:

  • Treats both sleep onset AND maintenance insomnia (your severe insomnia likely involves both) 1, 5
  • Half-life of 2.4 hours provides adequate sleep duration without excessive morning sedation 2, 5
  • Lower dependence potential than restarting zopiclone/eszopiclone 2
  • FDA-approved with strong evidence base 1, 2

Critical safety warning: The FDA has mandated lower starting doses (5 mg immediate-release) due to next-day impairment risks; use 10 mg only if 5 mg is insufficient 5

Alternative Options if Zolpidem Fails

Second-line: Suvorexant 10-20 mg (orexin receptor antagonist) 1, 2

  • Particularly effective for sleep maintenance (reduces wake after sleep onset by 16-28 minutes) 2
  • Different mechanism than zopiclone, avoiding cross-tolerance concerns 1
  • Not a controlled substance, beneficial given your withdrawal history 1

Third-line: Low-dose doxepin 3-6 mg 1, 2

  • Excellent for sleep maintenance with strong evidence 2
  • Reduces wake after sleep onset by 22-23 minutes 2
  • Non-addictive profile 1

Options to AVOID

Do NOT use eszopiclone (Lunesta): This is the S-isomer of zopiclone—essentially the same drug you just discontinued. 6, 7

  • Cross-tolerance is virtually certain 7
  • Will perpetuate the dependence cycle you're trying to break 7
  • Common adverse effects include unpleasant taste (17-26%), somnolence, dizziness 1

Do NOT use trazodone: The American Academy of Sleep Medicine explicitly recommends AGAINST trazodone for insomnia treatment. 8

  • Failed to demonstrate clinically significant sleep improvements versus placebo 8
  • Inferior to evidence-based alternatives 8

Do NOT combine benzodiazepines (like alprazolam) with other sedatives: 8

  • Additive CNS depression increases fall risk, respiratory depression, and psychomotor impairment 8
  • Higher dependence liability than non-benzodiazepine options 8

Treatment Duration and Monitoring

Use the lowest effective dose for 4-5 weeks maximum, then reassess. 2, 5

  • FDA approval is for short-term use (4-5 weeks) 2
  • Reevaluate need for continued pharmacotherapy at 4 weeks 2
  • If symptoms persist beyond 4-5 weeks, intensify CBT-I rather than continuing medication indefinitely 2
  • Monitor for tolerance development (requiring dose escalation) 5

Special Considerations

If you have hepatic impairment: Maximum zolpidem dose is 5 mg; avoid dose escalation 6

If elderly (≥65 years): Start zolpidem 5 mg, suvorexant 5 mg, or doxepin 3 mg due to increased sensitivity 2

Avoid high-fat meals: Taking zolpidem with or after heavy meals delays onset by ~1 hour and reduces effectiveness 6

Common pitfalls to avoid:

  • Do not take zolpidem unless you can dedicate 7-8 hours to sleep (next-day impairment risk) 5
  • Do not drive or operate machinery until you know how the medication affects you 5
  • Do not combine with alcohol or other CNS depressants 8
  • Do not abruptly discontinue after prolonged use; taper gradually 1

Expected Timeline

  • Days 1-7: Acute withdrawal symptoms from zopiclone should begin improving 3
  • Weeks 1-2: Sleep should noticeably improve with zolpidem + CBT-I 1
  • Weeks 2-4: Reassess medication need; many patients can transition to CBT-I alone 2
  • Beyond 4 weeks: If still requiring medication, consider switching to suvorexant or doxepin for longer-term use 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Alternative Sleep Medications to Lunesta (Eszopiclone)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Dependence on zopiclone: a case report.

Frontiers in psychiatry, 2025

Guideline

Non-Benzodiazepine Hypnotics for Insomnia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Eszopiclone: its use in the treatment of insomnia.

Neuropsychiatric disease and treatment, 2007

Guideline

Insomnio: Comparación de Evidencia entre Eszopiclona y Trazodona

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.